Loading...
01/11 03:33
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong underwriting and policyholder retention, but slight decreases in net income and investment income. The Q&A reveals confidence in growth strategy and stable competitive landscape, but concerns about medical inflation and large losses persist. Despite a positive book value increase, no new partnerships or significant guidance changes were announced. The market's competitive nature and lack of immediate expansion plans further balance the sentiment. Given these factors, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment rating.
Return on Average Equity 20.5%, reflecting a healthy return for the quarter.
Combined Ratio 90.6% for the quarter, indicating strong underwriting performance.
Voluntary Premiums Growth 10.6% year-over-year, driven by disciplined underwriting, robust new business production, and strong renewal performance.
Gross Premiums Written $80.3 million, a 7.2% increase from $74.9 million in Q3 2024, supported by audit premiums and voluntary premium growth.
Net Earned Premiums Growth 6.2% year-over-year, reflecting strong underwriting and policyholder retention.
Accident Year Loss Ratio 71%, consistent with the prior year quarter, with low frequency but higher severity year-over-year.
Favorable Reserve Development $8.9 million, primarily from accident years 2020 and prior, due to consistent claims handling practices.
Net Income $13.8 million or $0.72 per diluted share, compared to $14.3 million or $0.75 per diluted share in Q3 2024, reflecting a slight decrease.
Operating Net Income $10.6 million or $0.55 per diluted share, compared to $11.1 million or $0.58 per diluted share in Q3 2024, reflecting a slight decrease.
Underwriting and Other Expenses $22.1 million, up from $21.3 million in Q3 2024, resulting in an expense ratio of 31.1% compared to 31.7% in the prior year quarter, reflecting ongoing investment in growth.
Net Investment Income $6.6 million, a 12.3% decrease year-over-year, due to a decrease in average investable assets following the special dividend payment in Q4 2024.
Investment Portfolio Value $817 million at quarter-end, down from $899 million at September 30, 2024, reflecting the impact of the special dividend payment.
Book Value Per Share $14.47, a 7.1% increase year-to-date, reflecting strong financial performance.
Statutory Surplus $259 million, up from $235.1 million at year-end 2024, indicating a strong capital position.
Voluntary Premium Growth: Voluntary premiums on policies written in the quarter grew 10.6%, driven by new business production and strong retention.
Gross Premiums Written: Gross premiums written increased by 7.2% compared to Q3 2024, reaching $80.3 million.
Return on Average Equity: Achieved a 20.5% return on average equity for the quarter.
Combined Ratio: Reported a combined ratio of 90.6%, reflecting disciplined underwriting and operational efficiency.
Expense Ratio: The expense ratio improved to 31.1% from 31.7% in the prior year quarter, reflecting ongoing investments in growth.
Claims Handling Practices: Maintained consistent and disciplined claims handling practices, resulting in $8.9 million of favorable reserve development on prior accident years.
Capital Deployment Strategy: Declared a regular quarterly dividend of $0.39 per share and a $1 special dividend, reflecting a balanced approach to rewarding shareholders and supporting long-term growth.
Share Repurchases: Repurchased approximately 31,000 shares at an average cost of $43.72 per share, totaling $1.3 million.
Severity of Claims: Severity of claims continues to increase year-over-year, which could impact profitability and claims management.
Audit Premium Headwinds: Audit premiums decreased compared to the prior year, which could pose challenges to top-line growth.
Investment Income Decline: Net investment income decreased by 12.3% due to a reduction in average investable assets, which could affect overall financial performance.
Reinvestment Rate Moderation: Moderation in reinvestment rates compared to the previous quarter could limit future investment income growth.
Unrealized Losses in Held-to-Maturity Securities: The portfolio maintains a net unrealized loss position of $7.6 million, which could impact financial flexibility.
Growth Strategy: The company is focused on disciplined underwriting, robust new business production, and strong renewal performance to drive top-line growth. Voluntary premiums on policies written in the quarter grew 10.6%, and gross premiums written increased by 7.2%.
Capital Deployment: The Board of Directors declared a regular quarterly dividend of $0.39 per share and a $1 special dividend, reflecting a balanced approach to capital deployment. The company aims to reward shareholders while maintaining flexibility for business investment and long-term value creation.
Investment Portfolio: The reinvestment rate environment remains strong, with yields on new investments exceeding portfolio roll-off by 77 basis points. The portfolio tax-equivalent book yield is 3.9%, and the company maintains a high-quality investment portfolio with a double AA-minus average credit rating.
Expense Management: The expense ratio for the quarter was 31.1%, reflecting ongoing investments in growth opportunities within target markets.
Regular Quarterly Dividend: The Board of Directors declared a regular quarterly dividend of $0.39 per share.
Special Dividend: The Board of Directors declared a $1 special dividend payable on December 12, 2025, to shareholders as of record as of December 5, 2025.
Historical Dividend Performance: Over the past 13 years, AMERISAFE has declared nearly $50 per share in total dividends, including $12.68 in regular dividends and $37.25 in special dividends per share.
Share Repurchase: During the third quarter, the company repurchased roughly 31,000 shares at an average cost of $43.72 per share, totaling $1.3 million.
The earnings call presents a mixed picture: strong underwriting and policyholder retention, but slight decreases in net income and investment income. The Q&A reveals confidence in growth strategy and stable competitive landscape, but concerns about medical inflation and large losses persist. Despite a positive book value increase, no new partnerships or significant guidance changes were announced. The market's competitive nature and lack of immediate expansion plans further balance the sentiment. Given these factors, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment rating.
The earnings call presents a mixed picture: strong gross written premiums and book value per share growth are positive, but declining net income and increased expense ratio are concerning. The Q&A highlights management's focus on growth and risk management but also reveals some uncertainties, such as upward pressure on loss ratios and vague responses on key metrics. The lack of clear guidance and the absence of market cap data make it challenging to predict a strong movement. Thus, a neutral sentiment is appropriate, indicating minor stock price fluctuations.
The earnings call presented a mixed picture. Financial performance showed growth in premiums and a stable combined ratio, but net income and investment income declined. The dividend increase is positive, but the lack of a share buyback plan and higher expenses are concerning. The Q&A revealed some uncertainties, particularly regarding economic factors and competitive pressures. Overall, the positive and negative aspects balance each other, leading to a neutral sentiment.
The earnings call reveals mixed signals. While there's a dividend increase, which is positive, the overall financial performance shows declines in net income and investment income, causing concern. The Q&A highlights stable policy growth but also competitive pressures and unclear responses from management. Despite some optimism in policy retention, the financial metrics and management's evasiveness lead to a neutral outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
